The FDA approved adaptive deep brain stimulation (DBS) technology (BrainSense adaptive DBS and BrainSense electrode ...

BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s ...

Medtronic's FDA-approved BrainSense Adaptive DBS system revolutionizes Parkinson's therapy with real-time adjustments for ...

The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...

Brain scientists have developed DeepFocus, a novel technique to reach the deep brain without invasive surgery to treat mental ...

The therapy, known as adaptive deep brain stimulation, or aDBS, uses an implanted device that continuously monitors the brain for signs that Parkinson’s symptoms are developing. When it detects ...

Researchers from Carnegie Mellon University and Allegheny Health Network have developed a new method for deep brain ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

Carnegie Mellon researchers developed "DeepFocus," a new method for brain stimulation that combines transnasal and transcranial electrical stimulation for minimally invasive targeting of deep brain ...

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...

Side effects of deep brain stimulation in people to treat Parkinson's may include impulsivity and depression. Biomedical ...